ABSTRACT
Overview of platelet glycoprotein IIb/IIIa receptor antagonists in clinical use Platelet membrane glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents that block what has been termed ‘the final common pathway’ of platelet aggregation by inhibiting the binding of the GPIIb/IIIa integrin receptor with its primary ligand, fibrinogen. Several types of GPIIb/ IIIa inhibitors exist; three are currently available for clinical use.
